Search Structure Search
wx_img
Inquiry Form
  1. Home
  2. Lorlatinib

Lorlatinib

Pfizer announced longer-term follow-up results of the Phase 3 CROWN study at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. This study aims to evaluate the efficacy and safety of the third-generation anaplastic lymphoma kinase (ALK) inhibitor LORBRENA® (lorlatinib, available in Europe under the brand name LORVIQUA®) versus XALKORI® (crizotinib) in people with previously untreated, anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). The analysis showed that compared with the first-generation ALK inhibitors, the risk of disease progression or death in patients treated with lorlatinib continued to decrease by 81%, and the risk of brain metastasis progression was reduced by 94%.

(1S)-1-(5-fluoro-2-iodophenyl)ethanol
(1S)-1-(5-fluoro-2-iodophenyl)ethanol
CM336652
1454847-96-1
methyl 2-[(1R)-1-(2-aminopyridin-3-yl)oxyethyl]-4-fluorobenzoate
methyl 2-[(1R)-1-(2-aminopyridin-3-yl)oxyethyl]-4-fluorobenzoate
CM336707
1454847-99-4
Methyl(R)-2-(1-((2-amino-5-bromopyridin-3-yl)oxy )ethyl)-4-fluorobenzoate
Methyl(R)-2-(1-((2-amino-5-bromopyridin-3-yl)oxy )ethyl)-4-fluorobenzoate
CM361030
1454848-00-0
tert-butyl N-[(4-bromo-5-cyano-1-methylpyrazol-3-yl)methyl]-N-methylcarbamate
tert-butyl N-[(4-bromo-5-cyano-1-methylpyrazol-3-yl)methyl]-N-methylcarbamate
CM336697
1454848-24-8
Ethyl 4-Bromo-1,3-dimethyl-1H-pyrazole-5-carboxylate
Ethyl 4-Bromo-1,3-dimethyl-1H-pyrazole-5-carboxylate
CM313111
5775-89-3